Episomal Vector System for Integration-Free iPSC Generation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for generating integration/transgene-free induced pluripotent stem cells are inefficient, require excessive reprogramming factors, and pose safety concerns due to the use of strong oncogenes, while existing approaches from peripheral blood cells yield low numbers of viable stem cells suitable for therapeutic use.
Innovation Solution
An episomal vector system utilizing an oriP/EBNA1-based plasmid backbone with optimized transcription and reprogramming factor genes, such as oct4, sox2, and klf4, separated by self-cleavage peptide sequences, along with a spleen focus-forming virus promoter and post-transcriptional regulatory element Wpre, and an anti-apoptotic factor like BCL-XL, to generate integration-free induced pluripotent stem cells from peripheral blood cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If excisable polycistronic lentiviral vectors or transposons are used to generate integration-free iPSCs, then transgene-free status is achieved, but a separate step to remove transgenes is required after reprogramming
Solution Approach 1:
The patent extracts the transgene removal step entirely by using episomal vectors that naturally fail to integrate into the host genome. The episomal vectors express reprogramming factors temporarily and are then lost during cell division, eliminating the need for separate transgene removal steps required by lentiviral or transposon-based methods.
Solution Approach 2:
Instead of using integrating vectors and then removing transgenes (the conventional approach), the patent inverts the strategy by using non-integrating episomal vectors from the beginning. This reverses the logical sequence: rather than integrate then remove, the method never integrates, achieving transgene-free status naturally without additional removal steps.
2Reliability
If synthetic modified mRNA is used to produce integration-free iPSCs, then integration-free status is achieved, but daily addition of mRNA by lipofection is required
Solution Approach 1:
The patent uses episomal vectors that are transient and naturally lost during cell division, similar to the temporary nature of mRNA. However, unlike mRNA which requires daily addition, the episomal vectors are delivered once and persist long enough to complete reprogramming, then are naturally eliminated, reducing the frequency of intervention.
Solution Approach 2:
The episomal vectors are introduced before reprogramming begins and remain present throughout the entire reprogramming process. This preliminary action eliminates the need for repeated mRNA additions during reprogramming, as the vectors provide continuous expression of reprogramming factors until they are naturally lost during cell division.
3Ease of manufacture
If Epstein-Barr virus latent gene-based episomal vector is used, then integration-free iPSCs are generated with only one transfection, but five to seven additional reprogramming factor genes including strong oncogenes are required
Solution Approach 1:
The patent extracts the unnecessary reprogramming factors from the system. By using optimized episomal vectors expressing only the essential four Yamanaka factors (OCT4, SOX2, KLF4, c-MYC), the method eliminates the need for five to seven additional factors including strong oncogenes like simian virus 40 large T antigen that were required by previous EBV-based methods.
Solution Approach 2:
The patent changes the parameter of reprogramming factor composition by selecting a minimal set of four essential factors rather than five to seven factors. This parameter change reduces the inclusion of strong oncogenes while maintaining reprogramming efficiency, thereby improving safety for clinical applications.
4Reliability
If cord blood cells are used to generate iPSCs, then integration-free iPSCs can be produced, but the efficiency is too low for widespread clinical use
Solution Approach 1:
The patent changes the parameter of vector design by using optimized episomal vectors with improved reprogramming factor expression and combination. This parameter change increases reprogramming efficiency from the previously very low levels achieved with cord blood cells to levels suitable for clinical applications, while maintaining the integration-free status.
Data Source
AI summary
A vector for generating induced pluripotent stem cells from human target cells comprising a) a vector backbone, b) exactly two, three or four transcription and reprogramming factor genes, each gene separated by a 2a self-cleavage peptide sequence, c) a spleen focus-forming virus promoter, and d) a post-transcriptional regulatory element Wpre, with or without an anti-apoptotic factor gene. A method for generating integration-free induced pluripotent stem cells, the method comprising: a) providing target cells, b) providing one or more than one vector according to the present invention, c) transducing or transfecting the target cells with the one or more than one vector, and d) culturing the transduced or transfected cells in a cell culture, thereby generating integration-free induced pluripotent stem cells.